Canaccord raised the firm’s price target on Neurocrine to $144 from $132 and keeps a Buy rating on the shares. The target increase reflects the company’s positive top-line data from its CAHtalyst Phase 3 study for crinecerfont in adult patients with congenital adrenal hyperplasia (CAH) and noted the trial hit statistical significance on its primary and key secondary endpoints.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $111 from $100 at BMO Capital
- Neurocrine announces ‘positive’ data from Phase 3 study of crinecerfont
- Neurocrine initiates Phase 1 study of NBI-1117570
- Neurocrine’s Ingrezza shows improvement in tardive dyskinesia study
- Neurocrine presents new INGREZZA capsules data
